Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

miR-195 inhibits cell proliferation and angiogenesis in human prostate cancer by downregulating PRR11 expression.

Cai C, He H, Duan X, Wu W, Mai Z, Zhang T, Fan J, Deng T, Zhong W, Liu Y, Zhong W, Zeng G.

Oncol Rep. 2018 Apr;39(4):1658-1670. doi: 10.3892/or.2018.6240. Epub 2018 Jan 31.

2.

The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.

Kim J, Park JS, Ham WS.

Investig Clin Urol. 2017 Sep;58(5):307-316. doi: 10.4111/icu.2017.58.5.307. Epub 2017 Aug 8. Review.

3.

Interpreting Patient Reported Urinary and Sexual Function Outcomes across Multiple Validated Instruments.

Vertosick EA, Vickers AJ, Cowan JE, Broering JM, Carroll PR, Cooperberg MR.

J Urol. 2017 Sep;198(3):671-677. doi: 10.1016/j.juro.2017.03.121. Epub 2017 Mar 22.

PMID:
28342935
4.

Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder.

Chung SD, Kao LT, Lin HC, Xirasagar S, Huang CC, Lee HC.

PLoS One. 2017 Mar 2;12(3):e0173266. doi: 10.1371/journal.pone.0173266. eCollection 2017.

5.

Risk stratification for disease progression in pT3 prostate cancer after robot-assisted radical prostatectomy.

Hong JH, Kwon YS, Kim IY.

Asian J Androl. 2017 Nov-Dec;19(6):700-706. doi: 10.4103/1008-682X.193569.

6.

More Judicious Use of Expectant Management for Localized Prostate Cancer during the Last 2 Decades.

Eifler JB, Alvarez J, Koyama T, Conwill RM, Ritch CR, Hoffman KE, Resnick MJ, Penson DF, Barocas DA; Collaborators.

J Urol. 2017 Mar;197(3 Pt 1):614-620. doi: 10.1016/j.juro.2016.10.067. Epub 2016 Oct 27.

7.

Danish Prostate Cancer Registry - methodology and early results from a novel national database.

Helgstrand JT, Klemann N, Røder MA, Toft BG, Brasso K, Vainer B, Iversen P.

Clin Epidemiol. 2016 Sep 27;8:351-360. eCollection 2016.

8.

A retrospective analysis of Victorian and South Australian clinical registries for prostate cancer: trends in clinical presentation and management of the disease.

Ruseckaite R, Beckmann K, O'Callaghan M, Roder D, Moretti K, Millar J, Evans S.

BMC Cancer. 2016 Aug 5;16:607. doi: 10.1186/s12885-016-2655-9.

9.

Prostate Cancer Care Before and After Medicare Eligibility.

Huesch MD, Ong MK.

Inquiry. 2016 May 10;53. pii: 0046958016647298. doi: 10.1177/0046958016647298. Print 2016.

10.

The Potential of MicroRNAs as Prostate Cancer Biomarkers.

Fabris L, Ceder Y, Chinnaiyan AM, Jenster GW, Sorensen KD, Tomlins S, Visakorpi T, Calin GA.

Eur Urol. 2016 Aug;70(2):312-22. doi: 10.1016/j.eururo.2015.12.054. Epub 2016 Jan 22. Review.

11.

Development of South Australian-Victorian Prostate Cancer Health Outcomes Research Dataset.

Ruseckaite R, Beckmann K, O'Callaghan M, Roder D, Moretti K, Zalcberg J, Millar J, Evans S.

BMC Res Notes. 2016 Jan 22;9:37. doi: 10.1186/s13104-016-1855-3.

12.

Post-prostatectomy incontinence: Etiology, evaluation, and management.

Singla N, Singla AK.

Turk J Urol. 2014 Mar;40(1):1-8. doi: 10.5152/tud.2014.222014. Review.

13.

Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study.

Garcia-Albeniz X, Chan JM, Paciorek A, Logan RW, Kenfield SA, Cooperberg MR, Carroll PR, Hernán MA.

Eur J Cancer. 2015 May;51(7):817-24. doi: 10.1016/j.ejca.2015.03.003. Epub 2015 Mar 17.

14.

Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.

Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL.

JAMA Intern Med. 2014 Sep;174(9):1460-7. doi: 10.1001/jamainternmed.2014.3028.

15.

Geriatric considerations in the treatment of advanced prostate cancer.

Kessler ER, Flaig TW.

F1000Prime Rep. 2014 May 6;6:33. doi: 10.12703/P6-33. eCollection 2014. Review.

16.

Radiotherapy after radical prostatectomy: treatment recommendations differ between urologists and radiation oncologists.

Lavallée LT, Fergusson D, Mallick R, Grenon R, Morgan SC, Momoli F, Witiuk K, Morash C, Cagiannos I, Breau RH.

PLoS One. 2013 Nov 4;8(11):e79773. doi: 10.1371/journal.pone.0079773. eCollection 2013.

17.

Development of prostate cancer research database with the clinical data warehouse technology for direct linkage with electronic medical record system.

Choi IY, Park S, Park B, Chung BH, Kim CS, Lee HM, Byun SS, Lee JY.

Prostate Int. 2013;1(2):59-64. doi: 10.12954/PI.12015. Epub 2013 Jun 30.

18.

Impact of folate intake on prostate cancer recurrence following definitive therapy: data from CaPSURE™.

Tomaszewski JJ, Richman EL, Sadetsky N, O'Keefe DS, Carroll PR, Davies BJ, Chan JM.

J Urol. 2014 Apr;191(4):971-6. doi: 10.1016/j.juro.2013.09.065. Epub 2013 Oct 3.

19.

Treatment and Mortality in Men with Localized Prostate Cancer: A Population-Based Study in California.

Sieh W, Lichtensztajn DY, Nelson DO, Cockburn M, West DW, Brooks JD, Chang ET.

Open Prost Cancer J. 2013;6:1-9.

20.

Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry.

Efstathiou JA, Nassif DS, McNutt TR, Bogardus CB, Bosch W, Carlin J, Chen RC, Chou H, Eggert D, Fraass BA, Goldwein J, Hoffman KE, Hotz K, Hunt M, Kessler M, Lawton CA, Mayo C, Michalski JM, Mutic S, Potters L, Rose CM, Sandler HM, Sharp G, Tomé W, Tran PT, Wall T, Zietman AL, Gabriel PE, Bekelman JE.

J Oncol Pract. 2013 May;9(3):e90-5. doi: 10.1200/JOP.2013.001003.

Supplemental Content

Support Center